Autoimmune Disease Innovations: How Biotech Startups Are Revolutionizing Multiple Sclerosis Treatment
Thursday, 24 October 2024, 01:56
Introduction to Autoimmune Disease in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, autoimmune disease impacting the central nervous system (CNS). It is characterized by varying symptoms, including fatigue, mobility issues, and cognitive difficulties, significantly affecting patients' quality of life.
Leading Biotech Companies Advancing MS Therapies
- Biogen: The company is advancing its leading candidate, BIIB091, a next-generation BTK inhibitor.
- Immunic Therapeutics: Vidofludimus calcium (IMU-838) targets neuroprotection while inhibiting overactive immune cell metabolism.
- Kyverna Therapeutics: KYV-101, utilizing CAR-T therapy principles, is under investigation for treatment efficacy in MS.
- Progentos Therapeutics: This startup focuses on remyelination therapies aiming to counteract damage from MS.
- TG Therapeutics: Known for BRIUMVI, a monoclonal antibody showing promising results in treating different MS forms.
- Zenas BioPharma: Obexelimab is a bivalent monoclonal antibody currently in phase 2 trial stages to evaluate its effectiveness against MS.
Future of Multiple Sclerosis Treatment
With emerging therapies targeting various aspects of multiple sclerosis, we can expect a substantial shift in treatment paradigms. The multiple sclerosis drug market is projected to reach $38.94 billion by 2032, underscoring the rising need for effective treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.